Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Spring on the Road
Spring Wellness
Premier Home Stylle Tour 2024
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
2024 Auction
2024 Readersâ Choice Awards
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Altamira Therapeutics Ltd
Altamira Therapeutics Announces Filing of Provisional Patent Application for OligoPhore Nanoparticles with siRNA Targeting p65 Protein in Treatment of Cancer and Inflammation
May 01, 2024
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Tickers
CYTO
Altamira Therapeutics Announces Publication of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis in Top Peer Reviewed Journal
April 24, 2024
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Tickers
CYTO
Altamira Therapeutics Provides Business Update, Reports Full Year 2023 Financial Results
April 10, 2024
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Tickers
CYTO
Altamira Therapeutics to Host Full Year 2023 Financial Results and Business Update Call on April 10, 2024
April 04, 2024
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Tickers
CYTO
Altamira Therapeutics Announces Collaboration with Univercells Group on Nanoparticle-Delivered mRNA Vaccines
March 25, 2024
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Tickers
CYTO
Altamira Therapeutics’ Peptide-Based Delivery Platform Shown to Enhance Potency of Commonly Used Gene Delivery Method as Published in Peer-Reviewed Journal
February 07, 2024
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Tickers
CYTO
Altamira Therapeutics Files Second Provisional Patent Application for OligoPhore Nanoparticles Targeting Different KRAS Mutations in Cancer Treatment
January 24, 2024
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Tickers
CYTO
Altamira Therapeutics to Present at 3rd Annual mRNA-Based Therapeutics Summit
January 08, 2024
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Tickers
CYTO
Altamira Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
December 29, 2023
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Tickers
CYTO
Altamira Therapeutics Provides Investor and Business Update
December 11, 2023
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Tickers
CYTO
Altamira Therapeutics to Host Investor & Business Update Call on December 11th
December 05, 2023
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Tickers
CYTO
Altamira Therapeutics Regains Compliance with Nasdaq Minimum Stockholders' Equity Requirement
November 29, 2023
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Tickers
CYTO
Altamira Therapeutics Announces Partial Spin-Off of Bentrio® Business
November 17, 2023
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Tickers
CYTO
Altamira Therapeutics Announces European Patent Office Decision to Grant for Patent Application Covering Intranasal Betahistine
November 10, 2023
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Tickers
CYTO
Altamira Therapeutics Reports Additional Significant Efficacy Outcomes from Bentrio Clinical Trial in Seasonal Allergic Rhinitis
September 14, 2023
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Tickers
CYTO
Altamira Therapeutics Provides Business Update and First Half 2023 Financial Results
September 12, 2023
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Tickers
CYTO
Altamira Therapeutics to Host First Half 2023 Financial Results and Business Update Call on September 12th
September 06, 2023
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Tickers
CYTO
Altamira Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference September 11-13
August 23, 2023
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Tickers
CYTO
Altamira Therapeutics and Pharma Nordic Collaborate for Marketing and Distribution of Bentrio in Scandinavia
July 20, 2023
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Tickers
CYTO
Altamira Therapeutics Announces Publication of Positive Results from Clinical Trial with Bentrio in House Dust Mite Allergy in Leading Peer Reviewed Journal
July 17, 2023
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Tickers
CYTO
Altamira Therapeutics Announces Collaboration with Heqet Therapeutics on Nanoparticle-Delivered Non-Coding RNAs for Cardiac Regeneration
July 05, 2023
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Tickers
CYTO
Altamira Therapeutics’ SemaPhore Delivery Platform Shows Significant Synergis-tic Effects of ZBTB46 mRNA with PD1 Immunotherapy in Control of Tumor Growth in Animal Model
March 22, 2023
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Tickers
CYTO
Altamira Therapeutics Files Provisional Patent Application for OligoPhore Nanoparticles Targeting Different KRAS Mutations in Cancer Treatment
February 27, 2023
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Tickers
CYTO
Altamira Therapeutics Provides Business Update
January 27, 2023
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Tickers
CYTO
Altamira Therapeutics Provides Update on Clinical Trials with Bentrio
January 24, 2023
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Tickers
CYTO
Altamira Therapeutics to Present at 2nd Annual mRNA-Based Therapeutics Summit Europe Conference January 24th to 26th
January 10, 2023
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Tickers
CYTO
Altamira Therapeutics Provides Year-End 2022 Business Update
December 19, 2022
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Tickers
CYTO
Altamira Therapeutics Provides Business Update and First Half 2022 Financial Results
November 30, 2022
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Tickers
CYTO
Altamira Therapeutics Announces Launch of Bentrio in Hong Kong by its Partner Nuance Pharma
November 30, 2022
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Tickers
CYTO
Altamira Therapeutics to Participate at TIDES Europe Oligonucleotide and Peptide Therapeutics Hybrid Event
November 10, 2022
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Tickers
CYTO
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.